BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, May 12, 2024
See today's BioWorld
Home
» Nodus adds funding to advance PARG inhibitor, other DDR programs
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Nodus adds funding to advance PARG inhibitor, other DDR programs
Feb. 7, 2023
By
Nuala Moran
No Comments
Nodus Oncology Ltd. closed on the first £2.4 million (US$2.9 million) of £12 million it expects to raise in a number of tranches over the next 12 months, to source and take forward third-generation DNA damage response (DDR) programs.
BioWorld
Financings
Cancer